Kinase News and Research

RSS

Promising new agent against sarcomas affecting children

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.

3 Dec 2011

MK 1775 shows promise against sarcomas

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla.

3 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Lapatinib could extend survival in women with Her2-positive breast cancer

Treatment with lapatinib could extend survival in women with Her2-positive breast cancer that has spread to the brain, according to research published in the British Journal of Cancer.

30 Nov 2011

Most people with Timothy syndrome mutation have autistic symptoms

Neuroscientists at Stanford University School of Medicine have homed in on potential differences in autistic people's brain cells by studying brainlike spheres grown in an elaborate process from skin cells.

28 Nov 2011

Researchers discover molecular sensor that detects wound-induced hydrogen peroxide

Hydrogen peroxide isn't just that bottled colorless liquid in the back of the medicine cabinet that's used occasionally for cleaning scraped knees and cut fingers. It's also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system's first responders, to rush to the wound to fight microorganisms, remove damaged tissue and then start the inflammation process.

22 Nov 2011

Two genetic rearrangements may trigger 5 to 7% of breast cancers

Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.

20 Nov 2011

Blocking CaM kinase may help prevent cardiac rupture

For people who initially survive a heart attack, a significant cause of death in the next few days is cardiac rupture -- literally, bursting of the heart wall. A new study by University of Iowa researchers pinpoints a single protein as the key player in the biochemical cascade that leads to cardiac rupture.

18 Nov 2011

MU scientist examines how enzymes influence immune system's ability to fight infection

The influenza virus remains a worldwide threat to humans, causing an average of 36,000 deaths and 200,000 hospitalizations each year in the United States alone. As health care professionals prepare for another flu season, a University of Missouri scientist is studying how two enzymes could be used to stop the virus in its tracks.

18 Nov 2011

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

New treatment may be on the horizon for neuroendocrine prostate cancers

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.

17 Nov 2011

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

17 Nov 2011

Women with inflammatory breast cancer now have a chance of treatment

Women with the deadliest and rarest form of breast cancer now have a chance of treatment where once their options were severely limited, thanks to a new discovery by George Mason University researchers.

15 Nov 2011

Amplification of ALK gene may drive rapid breast cancer metastasis

Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience.

14 Nov 2011

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

ArQule, Daiichi Sankyo enter license agreement for development of new AKT inhibitor

ArQule, Inc. and Daiichi Sankyo, Co. Ltd. announced today the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies' November 2008 agreement to collaborate on research utilizing the AKIP (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors.

10 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

Lapatinib drug could also treat head and neck cancers

A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer - particularly head and neck cancers, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

8 Nov 2011